Mereo BioPharma (MREO) Non-Current Assets (2017 - 2026)

Mereo BioPharma (MREO) has 10 years of Non-Current Assets data on file, last reported at $580000.0 in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $580000.0, down 59.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.9 million (down 46.54% YoY), and the FY2025 annual result was $897000.0, down 44.87% from the prior year.
• Non-Current Assets fell to $580000.0 in Q1 2026 per MREO's latest filing, from $897000.0 in the prior quarter.
• Over five years, Non-Current Assets peaked at $30.4 million in Q4 2022 and troughed at $580000.0 in Q1 2026.
• A 5-year average of $4.3 million and a median of $1.6 million in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2023: Non-Current Assets slipped 16.67% in 2022, then sank 91.0% in 2023.
• A 5-year view of Non-Current Assets shows it stood at $30.4 million in 2022, then slumped by 91.0% to $2.7 million in 2023, then plunged by 40.6% to $1.6 million in 2024, then sank by 44.87% to $897000.0 in 2025, then plunged by 35.34% to $580000.0 in 2026.
• Business Quant data shows MREO's Non-Current Assets at $580000.0 in Q1 2026, $897000.0 in Q4 2025, and $1.2 million in Q3 2025.